Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.44 |
| ▸ | ABAT | P80404 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013285 | 1.00 | TAAR1 (0.55) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL1013283 | 1.00 | TAAR1 (0.55) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL7870676 | 0.98 | TAAR1 (0.53) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL9000001 | 0.98 | TAAR1 (0.53) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL4623579 | 0.83 | CA12 (0.41) | TAAR1SLC6A2SLC7A5CA2 | |
| SCHEMBL15951403 | 0.83 | TAAR1 (0.59) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL8855721 | 0.83 | TSHR (0.39) | TAAR1SLC6A2SLC7A5CA2 | |
| SCHEMBL2269394 | 0.81 | CYP3A4 (0.42) | TAAR1SLC7A5CA2 | |
| SCHEMBL242931 | 0.81 | CYP3A4 (0.42) | TAAR1SLC7A5CA2 | |
| SCHEMBL6670843 | 0.81 | HRH3 (0.48) | TAAR1SLC6A2ABATCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388939-A1 | RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF L-DOPA, DOPAMINE, S-NOROCLAURINE OR DERIVATIVES THEREOF | RIVER STONE BIOTECH APS (DK) | 2025-12-25 | — | — | US | claimed |
| US-12497638-B2 | Methods of producing epimerases and benzylisoquinoline alkaloids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-12-16 | — | — | US | claimed |
| US-12371722-B2 | Recombinant host cells with improved production of L-DOPA, dopamine, S-noroclaurine or derivatives thereof | RIVER STONE BIOTECH APS (DK) | 2025-07-29 | — | — | US | claimed |
| US-20240209403-A1 | METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-06-27 | — | — | US | claimed |
| US-11884949-B2 | Methods of producing morphinan alkaloids and derivatives | ANTHEIA, INC. (US) | 2024-01-30 | — | — | US | claimed |
| WO-2024015152-A1 | TETRAHYDROPAPAVERINE-PRODUCING MICROBES AND METHODS OF MAKING AND USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-01-18 | — | — | WO | claimed |
| EP-4253525-A2 | METHODS OF PRODUCING EPIMERASES AND BENZYLISOQUINOLINE ALKALOIDS | The Board of Trustees of the Leland Stanford Junior University (US) | 2023-10-04 | — | — | EP | claimed |
| CN-105829541-B | Microorganisms producing benzylisoquinoline alkaloid (BIA) precursors and methods of making and using the same | 小利兰·斯坦福大学托管委员会 | 2022-08-12 | — | — | CN | claimed |
| US-20220112528-A1 | RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF L-DOPA, DOPAMINE, S-NOROCLAURINE OR DERIVATIVES THEREOF | RIVER STONE BIOTECH APS (DK) | 2022-04-14 | — | — | US | claimed |
| CN-122038251-A | Preparation method and application of microorganism for producing 1-phenethyl isoquinoline | 中国科学院分子植物科学卓越创新中心 | 2026-05-15 | — | — | CN | disclosed |
| EP-3725797-B1 | STABILIZED LIQUID ENZYME COMPOSITIONS | NOVOZYMES AS (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4705447-A1 | PERFORMANCE-ENHANCED PROTEASE VARIANTS | Henkel AG & Co. KGaA (DE) | 2026-03-11 | — | — | EP | disclosed |
| US-20250388939-A1 | RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF L-DOPA, DOPAMINE, S-NOROCLAURINE OR DERIVATIVES THEREOF | RIVER STONE BIOTECH APS (DK) | 2025-12-25 | — | — | US | disclosed |
| US-20250388939-A1 | RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF L-DOPA, DOPAMINE, S-NOROCLAURINE OR DERIVATIVES THEREOF | RIVER STONE BIOTECH APS (DK) | 2025-12-25 | — | — | US | disclosed |
| US-20070031855-A1 | Receptor for a bacillus thuringiensis toxin | BULLA LEE A | 2007-02-08 | — | — | US | disclosed |
| US-5952189-A | SCREENING FOR ENZYME INHIBITORS FOR ANTIPROLIFERATIVE AGENTS, ANTITUMOR AGENTS, TREATMENT FOR LEUKEMIA, ACQUIRED IMMUNE DEFICIENCY SYNDROME, NERVOUS SYSTEM DISORDERS | PANORAMA RESEARCH, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| CN-1142830-A | Macrocyclic difluorostatone derivatives useful as antiviral agents | MERRELL DOW PHARMA (US) | 1997-02-12 | — | — | CN | disclosed |
| WO-1996022962-A9 | BUTYRYL-TYROSINYL SPERMINE, ANALOGS THEREOF AND METHODS OF PREPARING AND USING SAME | — | 1996-10-03 | — | — | WO | disclosed |
| EP-0585412-A1 | INCREASING BLOOD-BRAIN BARRIER PERMEABILITY WITH PERMEABILIZER PEPTIDES | ALKERMES, INC. (US) | 1994-03-09 | — | — | EP | disclosed |
| WO-1992018529-A1 | INCREASING BLOOD-BRAIN BARRIER PERMEABILITY WITH PERMEABILIZER PEPTIDES | ALKERMES, INC. (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388939-A1 | RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF L-DOPA, DOPAMINE, S-NOROCLAURINE OR DERIVATIVES THEREOF | DBH, DDT, COMT | TAAR1 1263/4885SLC6A2 257/4885SLC7A5 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.